Identification and validation of TP53/p53 status as a prognostic marker in penile squamous cell carcinoma: Evidence from a cohort study and meta-analysis.

Urol OncolJul 24, 2026 (epub)
Clinical ResearchOncology (Medical)Urology

Zijian Cai, Hongtao Jin, Yepeng Guo et al.

✦ AI-curated · Sources linked

In 30 seconds

This study investigated the prognostic value of TP53/p53 status in penile squamous cell carcinoma (pSCC) using a single-center cohort and a meta-analysis. The findings revealed that p53 mutant-pattern expression significantly increased the risk of lymph node metastasis (OR = 7.56) and was associated with inferior overall survival (HR = 6.15) and cancer-specific survival (HR = 7.92).

Key findings

  • p53 mutant-pattern expression was linked to a 7.56-fold increased risk of lymph node metastasis.
  • Overall survival was significantly poorer with a hazard ratio of 6.15 for p53 mutant-pattern expression.
  • Cancer-specific survival showed a hazard ratio of 7.92 associated with p53 mutations.
  • Meta-analysis confirmed aberrant p53/TP53 status correlates with elevated lymph node metastasis (pooled OR = 2.90).

Why it matters

Understanding the prognostic implications of TP53/p53 status in pSCC can enhance risk stratification and inform treatment decisions, potentially leading to more personalized management strategies for patients with this rare malignancy.

Source

PubMed · PMID 42497775

Published in Urol Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.